Postexposure prophylaxis after sexual assaults: a prospective cohort study.
OBJECTIVE
The objective of this study was to evaluate HIV postexposure prophylaxis (PEP) protocol in rape victims.


METHODS
The victims were assigned to 1 of 3 categories, according to the severity of exposure (I-low, II-moderate, III-high). HIV PEP was provided to victims in groups II (Zdv + 3TC) and III (Zdv + 3TC + PI) until 72 hours after exposure. The follow-up was 6 months.


RESULTS
From May 1997 to October 2001, 347 victims were attended. PEP was offered to 278 victims (141 in group II and 137 in group III). Side effects were more common in group III (P <0.01). No seroconversion was diagnosed in the 180 victims that completed the follow-up. Univariate analysis showed that the schooling level, knowledge of the aggressor's HIV status, and the use of PEP were associated with compliance.


CONCLUSIONS
Triple therapy was associated with side effects, which suggested that drug regimes should be reviewed. The variables related to a high risk of HIV transmission were also significant for compliance.
Garcia
Márcia Teixeira
MT
Infectious Diseases Division, Faculty of Medical Sciences, Universidade Estadual de Campinas, UNICAMP, São Paulo, Brazil.
Figueiredo
Rosely Moralez
RM
Moretti
Maria Luiza
ML
Resende
Máriangela Ribeiro
MR
Bedoni
Aloásio J
AJ
Papaiordanou
Priscila Maria O
PM
D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D001938:Brazil / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000008:administration & dosage; D010349:Patient Compliance; D011446:Prospective Studies; D011902:Rape; D012749:Sexually Transmitted Diseases / Q000453:epidemiology / Q000517:prevention & control; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D019888:Nelfinavir